In experiments on cell cultures, both of these inhibitors succeeded in breaking various forms of the TKI resistance: including forms caused
by additional mutations of the gene Bcr - Abl as well as those caused by large quantities of the protein Gab2.
Not exact matches
The authors conclude
by raising what they consider to be «a broader ethical problem with OAR,» stating that this procedure amounts to nothing more than human cloning with the
additional twist of introducing a genetic
mutation» ominously concluding that a «combination of wrongs can not make the end result good.»
«When cancer comes back, it's genetically very similar to the original tumor but often with
additional mutations that may give cancer cells new strategies to survive attack
by whatever drugs are thrown at them.
The researchers considered two possible explanations: Disease suppression might be the result of one or two
additional substitutions on the same gene that buffer the harmful effect of the
mutation; or suppression may be caused
by numerous small substitutions throughout the genome that form an aggregate «shield.»
For horses around the world, the same genetic
mutation — bred into the horses
by humans — underlies these
additional gaits, researchers report in the March issue of Animal Genetics.
[69,72] In gastrointestinal stromal tumors (GIST), secondary resistance to KIT inhibition is caused primarily
by development of
additional KIT
mutations.
In all 7 cases, the results suggest a linear model of clonal evolution, in which progression from MDS to sAML was characterized
by persistence of a single founder clone (defined
by ~ 200 - 700
mutations) and the outgrowth of at least one new subclone which contained dozens or hundreds of
additional mutations.
In the process, it gained
additional mutations, possibly via the DNA damage induced
by chemotherapy.
«That's why a lot of East Asians can't metabolize alcohol,» Pritchard said, «but
mutations in this pathway must have some
additional positive effect that has been favored
by natural selection.»
Fortunately, experiments done
by Dr. Jan Vijg at the Albert Einstein College of Medicine and others on
mutations (changes in base sequence in DNA) and
additional studies commissioned
by SENS Research Foundation on epimutations (changes in the arrangement of methyl groups) suggest that these latter kinds of alterations - the kind that accumulate in cells without triggering apoptosis or senescence or contributing to cancer - accumulate too slowly to make a difference with the current lifespan.
Derivatives of this basic construct included removal of the alternative exon 4
by deleting an Nhe I / Apa I fragment (nucleotides 12,259 — 12,543; Figure 3D); replacement of the genomic region covering exons 2 — 6 with the corresponding cDNA sequence (Sal I to Nco I; nucleotides 14,412 — 11,736; Figure 3E) plus
additional upstream sequence to allow for recombination with F56B12 (to the Xho I site at nucleotide 15,574); and introduction of a Met to Leu
mutation (M121L, ATG to CTG)
by PCR amplification with primers that included the sequence change (nucleotides 11,968 — 11,970; Figure 3F).
That caution was subsequently validated
by additional research that completely excluded the Phosducin gene and led to identification of gene and
mutation causing Type A PRA.
Additional research, funded
by the ESSFTA Foundation and the AKC Canine Health Foundation, has been initiated to help answer the questions that remain unexplained
by the discovery of this
mutation.
Additional research has been initiated to help answer the questions that remain unexplained
by discovery of this
mutation.